

Remarks

Applicants have amended the specification to update the priority information and to identify each amino acid sequence with the appropriate Sequence Identification Number in order to comply with the requirements of 37 C.F.R. 1.821 through 1.825.

Additionally, in the chart on page 19, line 25, the single letter codes for phenylalanine, asparagine and tryptophan have been added because these amino acids are used in SEQ ID NOS:12, 21, 26-29, 32 and 35-37 and this row of abbreviations was inadvertently left out. Two tables were inadvertently labelled as Table 5. The second Table 5 has been renumbered to Table 6. Table 6 has been amended to add the Sequence Identification Numbers and decrease the width of the table to less than five inches to comply with 37 CFR 1.58(c). In claim 15, line 43, a typographical error has been corrected from "gcardiomyopathy" to "cardiomyopathy", which agrees with the spelling on page 17, line 32.

On page 30, line 8, the sequence "PPPGMRRP" has been revised to correct a typographical error. The seventh base should be a "P", as evidenced by the sequence to which it is referring in line 7, "PPPGMRPP".

On page 30, line 28, the sequence "PPPGRMPP" has two bases transposed. The sequence has been revised to match the sequence to which it is referring in the protocol in the above paragraph and on lines 24 and 29, "PPPGMRPP".

On page 43, line 18, the reverse primer was inadvertently listed as being the same sequence as the forward primer. Page 43, line 1, states that the method of the invention is partially based on

the assay of the cited reference, Saito, et al., J. Exp. Med. 169:2192 (1989). The reverse primer of the invention has been corrected to reflect the reverse primer disclosed in the reference, which is attached for the examiner's review.


On page 46, line 16, an additional repeat was added to the eleven repeat sequence "GAGAGAGAGAGAGAGAGAGA", because the twelfth repeat was inadvertently deleted from the application. Support for this amendment is found at page 11, line 11, page 25, lines 26 and 29, and claims 8, 9, 19 and 20, wherein each occurrence of the glycine-alanine repeat sequence recites 12 repeats.

Applicants have amended the claims as originally presented to identify each amino acid sequence with the appropriate Sequence Identification Number in order to comply with the requirements of 37 C.F.R. 1.821 through 1.825. Applicants have further amended the claims to correct obvious errors of a typographical nature, including an error in numbering the claims as originally presented and resulting errors in claim dependency. No new subject matter has been added by way of this Preliminary Amendment.

Divisional of U.S.S.N. 10/012,756
Filed: June 27, 2003
PRELIMINARY AMENDMENT
Express Mail Label No.: EL 717 747 992 US
Date of Deposit: June 27, 2003

The claims as amended have been presented in recently revised format. Favorable consideration is respectfully requested.

Respectfully submitted,



Patrea L. Pabst
Reg. No. 31,284

Date: June 27, 2003

HOLLAND & KNIGHT LLP
2000 One Atlantic Center
1201 West Peachtree Street, N.E.
Atlanta, Georgia 30309-3400
(404) 817-8473 (Telephone)
(404) 817-8588 (Fax)

ATL1 #582762 v1